Courier service EMS
Other transport services
Air India Post International
Payment in the bank on the invoice
Darzalex 100mg belongs to antineoplastic drug required for multiple myeloma in patients who have getting at least 3 prior treatments.
Darzalex 100mg which is a human CD38-directed monoclonal antibody containing a proteasome inhibitor (PI) and an immunomodulatory agent or who are twice refractory to a PI and an immunomodulatory agent.
Daratumumab belongs to a monoclonal antibody whichaction by producing certain cells in the immune system aggression these cancer cells. One of the antigens signify on the surface of multiple myeloma cells is called CD38. Anti-CD38 antibodies, like daratumumab, aims multiple myeloma cells by binding to the CD38 antigen and then indicating the patient’s immune system to attack the tumour.
Maximum plasma concentration is 915 mcg/mL (weekly dosing)
Single treatment the volume of distribution in steady-state is 4.7 L and in combination
The half-life of Darzalex monotherapy is 18 days and combination therapy 22-23 days
Darzalex is indicated for the treatment of multiple myeloma the dosage for therapy as follows;
The Darzalex usual dose for weeks 1-6 is 16mg/kg infusion once weekly (total of 6 doses);
The Darzalex usual dose for Weeks 7-54 is 16 mg/kg IV infusion every 3 weeks (total of 16 doses)
The Darzalex usual dose for Week 55 onwards until disease progression is 16mg/kg IV infusion every 4 weeks.
The Darzalex usual dose for weeks 1-8 is 16mg/kg IV infusion every 2 weeks (total of 8 doses)
The Darzalex usual dose for Weeks 9-24 is 16mg/kg IV infusion every 2 weeks (total of 8 doses)
The Darzalex usual dose for Weeks 25 onward until disease progression is 16 mg/kg IV infusion every 4 weeks.
Combination with bortezomib and dexamethasone
Combination treatment with lenalidomide and dexamethasone
Combination treatment with pomalidomide and dexamethasone
Shortness of breath
Loss of appetite
Low blood counts
High blood pressure
Muscular chest pain
The drug Darzalex 100mg has no drug interaction studies have been performed
The drug Darzalex 100mg is contraindicated patients with hypersensitivity to the active substance or to any of the excipients
Darzalex 100mg may have increased neutropenia and/or thrombocytopenia induced by background therapy; monitor CBC counts periodically during treatment; regulate patients with neutropenia for signs of infection; dose delay may be necessary to allow recovery of neutrophils; no dose reduction is recommended, consider supportive care with growth factors and/or transfusion
Darzalex 100mg willconnect to CD38 on RBCs and may results in a positive indirect antiglobulin test (Coombs test)
Darzalex 100mg will cause false-positive results with serum protein electrophoresis (SPE) and immunofixation (IFE) assays
During pregnancy using of drug Darzalex100mg is not advisable due to drug mechanism of action, may cause fetal myeloid or lymphoid-cell depletion and reduced bone density.
Excretion into human milk is unknown. May be possible adverse reaction on the breast-fed child from Darzalex100mg
Store the drug at 20C – 80C
Avoid freezing or shake
Protect from light
If dose is missed then take it immediately soon, if time reach for next dose, then skip missed dose and continue regular schedule. Avoid taking two doses at a time.
Вижте офертите за акции. Хубаво е да се спаси!View all